A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Hours Before or After PfOS
- 31 March 2012
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 34 (3), 699-709
- https://doi.org/10.1016/j.clinthera.2012.01.011
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studiesClinical Therapeutics, 2009
- Effect of an Aluminum‐ and Magnesium‐Containing Antacid on the Bioavailability of Garenoxacin in Healthy VolunteersPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- Is It Really OK to Take This with Food? Old Interactions with a New TwistThe Journal of Clinical Pharmacology, 2002
- Food-Drug InteractionsDrugs, 2002
- Management of childhood idiopathic thrombocytopenic purpuraBritish Journal of Haematology, 1999
- Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and MagnesiumAntimicrobial Agents and Chemotherapy, 1999
- Design of Bioavailability/Bioequivalence StudiesDrug Information Journal, 1990
- Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacinCancer Cell, 1989